XTL Biopharmaceuticals CFO files initial Form 3

XTL Biopharmaceuticals Ltd filed an initial insider ownership report (Form 3) for Niv Segal, identified as Chief Financial Officer.

Accepted by SEC EDGAR 03/23/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd filed an initial insider ownership report (Form 3) for Niv Segal, identified as Chief Financial Officer. The filing does not list any reportable transactions or derivative positions and serves to establish Segal’s status as a reporting person for future ownership disclosures.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the XTLB Form 3 filing for Niv Segal show?

The Form 3 establishes that Niv Segal, the Chief Financial Officer of XTL Biopharmaceuticals, is now a reporting insider. It does not include any reported transactions or derivative positions, functioning mainly as a baseline ownership disclosure starting point.

Who is the reporting person in the XTLB Form 3 filing?

The reporting person is Niv Segal, identified in the filing as Chief Financial Officer of XTL Biopharmaceuticals. The form confirms his status as an insider who must report future changes in ownership through subsequent SEC filings when required.

Does the XTLB Form 3 filing report any insider share transactions?

No insider share transactions are reported in this Form 3. The transaction summary shows zero buys, zero sells, and no derivative transactions, indicating the document is purely an initial registration of insider reporting status for Niv Segal.

Are any derivative securities disclosed in the XTLB Form 3 for Niv Segal?

The filing does not list any derivative securities for Niv Segal. Both the derivative section and the summarized exercise-related counts are empty or zero, indicating there are no reportable options, warrants, or similar instruments included in this initial statement.

What is the purpose of this XTLB Form 3 insider filing?

This Form 3 serves to register Niv Segal, the Chief Financial Officer, as an insider subject to SEC ownership reporting rules. It creates a formal starting point so that any future changes in his beneficial ownership can be reported on Forms 4 or 5.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Segal Niv

(Last) (First) (Middle)

C/O XTL BIOPHARMACEUTICALS LTD.

26 BEN-GURION ST.

(Street)

RAMAT GAN 5112001

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
XTL BIOPHARMACEUTICALS LTD [ XTLB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Niv Segal	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)